Research
Hormonal
Novel mineralocorticoid receptor antagonists (MRAs) like finerenone reduce cardiovascular events and slow CKD progression in CMS patients with lower hyperkalemia risk compared to traditional MRAs.
If you have kidney disease and heart issues, ask your doctor about finerenone. It protects your kidneys and heart with a lower risk of dangerous potassium levels compared to older drugs. It is taken once daily.
GoodSupportsHIGH confidence
Unlike traditional MRAs, finerenone offers enhanced receptor selectivity and exhibited a lower risk of hyperkalemia, making it a safer option for CKD patients.
Why this rating
Supported by FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF trials.
Source
Expanding the Role of Novel Therapeutics in Cardiometabolic Syndrome: Beyond Heart Failure and Diabetes
Hyun‐Jin Kim · CardioMetabolic Syndrome Journal · 2025
DOI 10.51789/cmsj.2025.5.e4
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (e.g., semaglutide, liraglutide) significantly reduce major adverse cardiovascular events (MACE) and promote substantial weight loss in patients with or without diabetes, addressing core CMS components.Strong
- Combination therapy with ARNIs and SGLT2 inhibitors produces synergistic cardiovascular, metabolic, and renal benefits in cardiometabolic syndrome (CMS) patients, though implementation is hindered by hypotension risks and cost.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →